Table 1.
Patient characteristics at the time of enrolment
| N | Overall analysis cohort | Subset of patients with known date for symptom onset | Subset of patients with known date for first imaging evidence of pulmonary fibrosis | Patients excluded from analysis cohort |
| 498 | 347 | 454 | 56 | |
| Demographics | ||||
| Age, years | 70 (65 to 75) | 70 (64 to 75) | 71 (64 to 75) | 69 (64 to 76) |
| Male | 376 (75.5%) | 264 (76.1%) | 339 (74.7%) | 40 (71.4%) |
| White | 463 (95.1%) | 323 (94.7%) | 420 (94.6%) | 52 (96.3%) |
| Smoking history | ||||
| Non-smoker | 167 (33.7%) | 118 (34.2%) | 150 (33.2%) | 17 (30.4%) |
| Smoker | 329 (66.3%) | 227 (65.8%) | 302 (66.8%) | 39 (69.6%) |
| Current | 12 (2.4%) | 9 (2.6%) | 12 (2.7%) | 0 |
| Past | 317 (63.9%) | 218 (63.2%) | 290 (64.2%) | 39 (69.6%) |
| Comorbidities | ||||
| Gastro-oesophageal reflux disease | 265 (53.4%) | 194 (56.1%) | 239 (52.9%) | 31 (55.4%) |
| Coronary artery disease | 152 (30.7%) | 97 (28.0%) | 141 (31.3%) | 22 (39.3%) |
| Obstructive sleep apnoea | 143 (28.9%) | 102 (29.7%) | 128 (28.4%) | 21 (37.5%) |
| Diabetes | 105 (21.1%) | 77 (22.3%) | 93 (20.5%) | 14 (25.0%) |
| Hiatal hernia | 81 (16.4%) | 61 (17.7%) | 73 (16.2%) | 10 (18.2%) |
| Atrial fibrillation or flutter | 47 (9.5%) | 30 (8.7%) | 42 (9.3%) | 10 (17.9%) |
| Congestive heart failure | 36 (7.3%) | 19 (5.5%) | 34 (7.6%) | 5 (8.9%) |
| Family history | ||||
| Family history of ILD (grandparents, parents, siblings) | 79 (16.5%) | 54 (16.1%) | 69 (15.8%) | 11 (21.6%) |
| Supplemental oxygen | ||||
| With activity | 156 (31.8%) | 121 (35.5%) | 133 (29.7%) | 19 (33.9%) |
| At rest | 101 (20.5%) | 82 (24.0%) | 85 (19.0%) | 11 (19.6%) |
| Medications | ||||
| Proton pump inhibitor | 248 (55.4%) | 186 (58.7%) | 222 (54.7%) | 27 (52.9%) |
| Pirfenidone | 136 (27.3%) | 103 (29.7%) | 121 (26.7%) | 12 (21.4%) |
| Anticoagulant | 107 (23.9%) | 69 (21.8%) | 96 (23.7%) | 9 (17.6%) |
| Nintedanib | 107 (21.5%) | 74 (21.3%) | 100 (22.0%) | 19 (33.9%) |
| Oral steroid | 55 (12.3%) | 46 (14.5%) | 46 (11.3%) | 8 (15.7%) |
| Disease severity | ||||
| CPI | 52.7 (44.7 to 59.7) | 53.8 (45.5 to 60.5) | 52.5 (44.4 to 59.3) | 52.1 (46.0 to 57.5) |
| GAP score | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 5.0) |
| GAP stage | ||||
| I | 131 (31.2%) | 88 (29.3%) | 125 (33.0%) | 13 (28.3%) |
| II | 221 (52.6%) | 156 (52.0%) | 197 (52.0%) | 26 (56.5%) |
| III | 68 (16.2%) | 56 (18.7%) | 57 (15.0%) | 7 (15.2%) |
Data are median (Q1, Q3) or n (%). Additional patient characteristics are shown in online supplementary table 1.
CPI, composite physiological index; GAP, gender, age, lung physiology; ILD, interstitial lung disease.